WC
PBYI icon

Weatherbie Capital’s Puma Biotechnology PBYI Stock Holding History

Weatherbie Capital’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$55K Buy
+1,800
New +$77.8K 0.01% 62

Other funds holding PBYI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Weatherbie Capital's PBYI Position: Q4 2016 in Review

Weatherbie Capital reduced its Puma Biotechnology (PBYI) stake by 3.2% in Q4 2016, selling an estimated $367K and leaving 253,802 shares worth $7.79M. The position accounts for 0.98% of the portfolio, ranked #36.

Weatherbie Capital first reported a position in PBYI in Q2 2013 and has held it in 15 quarters since. The position peaked at $34.2M in Q1 2015. 128 funds tracked by Wall St. Rank hold PBYI as of Q4 2016.

  • Weatherbie Capital held 253,802 shares of Puma Biotechnology worth $7.79M as of Q4 2016.
  • Weatherbie Capital sold 8,484 Puma Biotechnology shares in Q4 2016, an estimated $367K.
  • Puma Biotechnology made up 0.98% of Weatherbie Capital's portfolio in Q4 2016, its #36 holding.
  • Weatherbie Capital first reported a position in Puma Biotechnology in Q2 2013 and has held it in 15 quarters since.
  • Weatherbie Capital's Puma Biotechnology position peaked at $34.2M in Q1 2015.
  • 128 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2016.

Based on Weatherbie Capital's 13F filing for Q4 2016, filed 14 Feb 2017.